Cytosorbents Corporation Stock Earnings Reports
Cytosorbents Earnings Calls
Release date | May 08, 2025 |
EPS estimate | -$0.0800 |
EPS actual | - |
Revenue estimate | 9.007M |
Revenue actual | - |
Expected change | +/- 7.36% |
Release date | Mar 31, 2025 |
EPS estimate | -$0.0700 |
EPS actual | -$0.0300 |
EPS Surprise | 57.14% |
Revenue estimate | 10.086M |
Revenue actual | 9.15M |
Revenue Surprise | -9.28% |
Release date | Nov 07, 2024 |
EPS estimate | -$0.0700 |
EPS actual | -$0.0800 |
EPS Surprise | -14.29% |
Revenue estimate | 9.453M |
Revenue actual | 8.613M |
Revenue Surprise | -8.89% |
Release date | Aug 13, 2024 |
EPS estimate | -$0.0900 |
EPS actual | -$0.0800 |
EPS Surprise | 11.11% |
Revenue estimate | 9.68M |
Revenue actual | 9.895M |
Revenue Surprise | 2.22% |
Last 4 Quarters for Cytosorbents
Below you can see how CTSO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Aug 13, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $0.90 |
EPS estimate | -$0.0900 |
EPS actual | -$0.0800 |
EPS surprise | 11.11% |
Date | Price |
---|---|
Aug 07, 2024 | $1.09 |
Aug 08, 2024 | $1.04 |
Aug 09, 2024 | $1.05 |
Aug 12, 2024 | $0.89 |
Aug 13, 2024 | $0.90 |
Aug 14, 2024 | $0.97 |
Aug 15, 2024 | $1.02 |
Aug 16, 2024 | $1.04 |
Aug 19, 2024 | $1.05 |
4 days before | -17.89% |
4 days after | 17.32% |
On release day | 7.99% |
Change in period | -3.67% |
Release date | Nov 07, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $0.90 |
EPS estimate | -$0.0700 |
EPS actual | -$0.0800 |
EPS surprise | -14.29% |
Date | Price |
---|---|
Nov 01, 2024 | $1.00 |
Nov 04, 2024 | $0.87 |
Nov 05, 2024 | $0.86 |
Nov 06, 2024 | $0.92 |
Nov 07, 2024 | $0.90 |
Nov 08, 2024 | $0.740 |
Nov 11, 2024 | $0.93 |
Nov 12, 2024 | $0.97 |
Nov 13, 2024 | $0.93 |
4 days before | -9.70% |
4 days after | 2.54% |
On release day | -18.05% |
Change in period | -7.41% |
Release date | Mar 31, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $1.00 |
EPS estimate | -$0.0700 |
EPS actual | -$0.0300 |
EPS surprise | 57.14% |
Date | Price |
---|---|
Mar 25, 2025 | $1.04 |
Mar 26, 2025 | $1.02 |
Mar 27, 2025 | $1.00 |
Mar 28, 2025 | $1.00 |
Mar 31, 2025 | $1.00 |
Apr 01, 2025 | $1.00 |
Apr 02, 2025 | $1.00 |
Apr 03, 2025 | $0.99 |
Apr 04, 2025 | $0.97 |
4 days before | -3.85% |
4 days after | -3.00% |
On release day | 0% |
Change in period | -6.73% |
Release date | May 08, 2025 |
Fiscal end date | Mar 30, 2025 |
Price on release | - |
EPS estimate | -$0.0800 |
EPS actual | - |
Date | Price |
---|---|
Apr 10, 2025 | $0.94 |
Apr 11, 2025 | $0.97 |
Apr 14, 2025 | $0.99 |
Apr 15, 2025 | $1.01 |
Apr 16, 2025 | $1.02 |
Cytosorbents Earnings Call Transcript Summary of Q4 2024
Cash Position: As of December 31, 2024, cash and cash equivalents stood at approximately $9.8 million, increasing to around $17 million on a pro forma basis, benefiting from a recent rights offering.
Product and Market Highlights
- CytoSorb Product: Over 270,000 devices used in 70+ countries, primarily addressing severe inflammation in critical care settings. 2024 sales driven by a 28% increase in direct international sales, despite flat growth in Germany.
- DrugSorb-ATR: Investigational device aimed at reducing perioperative bleeding in CABG surgery, submitted for regulatory approval in the U.S. and Canada. The total addressable market is projected to grow from $300 million to over $1 billion as the blood thinner Brilinta becomes generic.
Regulatory Updates
- FDA and Health Canada Applications: The FDA de novo application for DrugSorb-ATR is under interactive review, with anticipated approvals in 2025. Health Canada’s application is also in an advanced review stage.
Operational Strategies and Market Development
- Reorganization in Germany: Aimed at overcoming stagnant sales by enhancing customer engagement and overall sales team productivity, with short-term disruptions expected but longer-term growth anticipated.
- Sales Growth Strategy: Education on optimal treatment protocols for CytoSorb is expected to enhance adoption and utilization, particularly in severe inflammation cases.
Future Outlook
- Near-Term Goals: Targeting near cash flow breakeven by the end of 2025, primarily through sustainable revenue growth and improved cost management.
- Potential Launch of DrugSorb-ATR: Expected controlled market release and broader launch thereafter, with ongoing clinical data presentations aimed at building awareness and supporting sales efforts.
- Market Dynamics: Despite current challenges in Germany, overall international growth is strong, and potential regulatory approvals could provide significant market opportunities.
Conclusion
Investors should note CytoSorbents is on a path toward enhanced financial performance driven by sustained product demand and upcoming regulatory approvals for DrugSorb-ATR, which could unlock new revenue streams. The focus on operational efficiency and market development positions the company for potential long-term growth, underscoring its expanding role in critical care and cardiac surgery.